|
Headline: European banks patently disadvantaged Source: euromoney.com Date: June 2001 Author: Nigel Page European banks risk finding themselves outpaced by US competitors in the bid to protect and exploit their intellectual property. The great patents debate is not confined to the pharmaceuticals and biotech sectors. Press coverage may tend to focus on drugs and genetic patenting, but European financial institutions are ignoring this issue at their peril. Put simply, there is a substantial discrepancy between the way patents are viewed, and granted, in the US and their perceived importance in Europe. |
Access intelligence that drives action
To unlock this research, enter your email to log in or enquire about access
